PDCD1 and neoplasm: Additionally, combining eganelisib with both anti-CTLA4 and anti-PD-1 therapy results in CR rates of 30% in breast and 80% in melanoma models (B16-GM-CSF) and provided immunity to tumor re-implantation, whereas dual checkpoint inhibition alone did not result in any complete responses.